139 related articles for article (PubMed ID: 35223529)
21. [Long-term survival of personalized surgical treatment of locally advanced non-small cell lung cancer based on molecular staging].
Zhou Q; Shi Y; Chen J; Liu B; Wang Y; Zhu D; Zhang HT; Xu P; Gong Y; Chen G; Wei S; Qiu X; Niu Z; Chen X; Lei Z; Duan L; Wu Z
Zhongguo Fei Ai Za Zhi; 2011 Feb; 14(2):86-106. PubMed ID: 21342639
[TBL] [Abstract][Full Text] [Related]
22. Perioperative alectinib in a patient with locally advanced anaplastic lymphoma kinase positive non-small cell lung cancer (NSCLC): a case report.
Yue P; Zhang S; Zhou L; Xiang J; Zhao S; Chen X; Dong L; Yang W; Xiang Y
Transl Cancer Res; 2021 Aug; 10(8):3856-3863. PubMed ID: 35116684
[TBL] [Abstract][Full Text] [Related]
23. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
Gautschi O; Milia J; Filleron T; Wolf J; Carbone DP; Owen D; Camidge R; Narayanan V; Doebele RC; Besse B; Remon-Masip J; Janne PA; Awad MM; Peled N; Byoung CC; Karp DD; Van Den Heuvel M; Wakelee HA; Neal JW; Mok TSK; Yang JCH; Ou SI; Pall G; Froesch P; Zalcman G; Gandara DR; Riess JW; Velcheti V; Zeidler K; Diebold J; Früh M; Michels S; Monnet I; Popat S; Rosell R; Karachaliou N; Rothschild SI; Shih JY; Warth A; Muley T; Cabillic F; Mazières J; Drilon A
J Clin Oncol; 2017 May; 35(13):1403-1410. PubMed ID: 28447912
[TBL] [Abstract][Full Text] [Related]
24. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
[TBL] [Abstract][Full Text] [Related]
25. KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung.
Borrelli N; Giannini R; Proietti A; Alì G; Pelliccioni S; Niccoli C; Lucchi M; Melfi F; Mussi A; Basolo F; Fontanini G
Lung Cancer; 2013 Sep; 81(3):377-381. PubMed ID: 23891510
[TBL] [Abstract][Full Text] [Related]
26.
Zhang T; Wang H; Cai Z; Zhang S; Jiang C
Front Oncol; 2023; 13():1078076. PubMed ID: 37139148
[TBL] [Abstract][Full Text] [Related]
27. Response to Pralsetinib in Multi-Drug-Resistant Breast Cancer With CCDC6-RET Mutation.
Zhao J; Xu W; Zhuo X; Liu L; Zhang J; Jiang F; Shen Y; Lei Y; Hou D; Lin X; Wang C; Fu G
Oncologist; 2023 May; 28(6):e416-24. PubMed ID: 37141396
[TBL] [Abstract][Full Text] [Related]
28. KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease.
Viola D; Giani C; Mazzeo S; Ugolini C; Ciampi R; Molinaro E; Agate L; Borrelli N; Chella A; Fontanini G; Basolo F; Elisei R
J Clin Endocrinol Metab; 2017 Sep; 102(9):3091-3096. PubMed ID: 28911147
[TBL] [Abstract][Full Text] [Related]
29. Cerebrospinal Fluid Concentration of the RET Inhibitor Pralsetinib: A Case Report.
de Jong LAW; Sparidans RW; van den Heuvel MM
Case Rep Oncol; 2023; 16(1):1579-1585. PubMed ID: 38094038
[TBL] [Abstract][Full Text] [Related]
30. [Lung cancer treated abroad with receptor tyrosine kinase inhibitor].
Eide IJZ; Brustugun OT
Tidsskr Nor Laegeforen; 2021 Sep; 141():. PubMed ID: 34505490
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
Sun F; McCoach CE
Curr Treat Options Oncol; 2021 Jun; 22(8):72. PubMed ID: 34165651
[TBL] [Abstract][Full Text] [Related]
32. Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series.
Ribeiro MFSA; Alessi JVM; Oliveira LJC; Gongora ABL; Sacardo KP; Zucchetti BM; Shimada AK; de Galiza Barbosa F; Feher O; Katz A
Lung Cancer; 2020 Jan; 139():9-12. PubMed ID: 31698333
[TBL] [Abstract][Full Text] [Related]
33. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Subbiah V; Hu MI; Wirth LJ; Schuler M; Mansfield AS; Curigliano G; Brose MS; Zhu VW; Leboulleux S; Bowles DW; Baik CS; Adkins D; Keam B; Matos I; Garralda E; Gainor JF; Lopes G; Lin CC; Godbert Y; Sarker D; Miller SG; Clifford C; Zhang H; Turner CD; Taylor MH
Lancet Diabetes Endocrinol; 2021 Aug; 9(8):491-501. PubMed ID: 34118198
[TBL] [Abstract][Full Text] [Related]
34. Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.
Ferrara R; Auger N; Auclin E; Besse B
J Thorac Oncol; 2018 Jan; 13(1):27-45. PubMed ID: 29128428
[TBL] [Abstract][Full Text] [Related]
35. Frontline pembrolizumab for the treatment of RET-rearranged non-small cell lung cancer: A case report.
Baby S; Khalil F; Tanvetyanon T
Cancer Treat Res Commun; 2021; 28():100423. PubMed ID: 34166867
[TBL] [Abstract][Full Text] [Related]
36. Perioperative crizotinib in a patient with stage IIIB ALK-positive non-small cell lung cancer: a case report.
Tian Y; Huang J; Li C; Jiang L; Lin H; Lu P; Luo Q; Yang G
Ann Transl Med; 2020 Jun; 8(12):770. PubMed ID: 32647695
[TBL] [Abstract][Full Text] [Related]
37. Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC.
Tan AC; Seet AOL; Lai GGY; Lim TH; Lim AST; Tan GS; Takano A; Tai DWM; Tan TJY; Lam JYC; Ng MCH; Tan WL; Ang MK; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim WT; Tan EH; Lim TKH; Tan DSW
J Thorac Oncol; 2020 Dec; 15(12):1928-1934. PubMed ID: 32866654
[TBL] [Abstract][Full Text] [Related]
38. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis.
Tsuta K; Kohno T; Yoshida A; Shimada Y; Asamura H; Furuta K; Kushima R
Br J Cancer; 2014 Mar; 110(6):1571-8. PubMed ID: 24504365
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcomes of surgery after induction treatment in patients with pathologically proven N2-positive stage III non-small cell lung cancer.
Yang H; Yao F; Zhao Y; Zhao H
J Thorac Dis; 2015 Sep; 7(9):1616-23. PubMed ID: 26543609
[TBL] [Abstract][Full Text] [Related]
40. Detection of RET (rearranged during transfection) variants and their downstream signal molecules in RET rearranged lung adenocarcinoma patients.
Kim JO; Shin JY; Kim MY; Son KH; Jung CK; Kim TJ; Kim SY; Park JK; Sung SW; Bae SJ; Min HJ; Kang JH
Surg Oncol; 2018 Mar; 27(1):106-113. PubMed ID: 29549897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
